


Local Participation. Lasting Impact.



At Advanced Heart and Vascular Institute of Hunterdon, clinical research connects our community with the questions shaping the future of cardiovascular care. This fall, we celebrate an upcoming national presentation from a study our patients helped advance, prepare to launch a new peripheral artery disease trial, and continue our work across cardiovascular prevention and treatment.

FROM HUNTERDON TO THE NATIONAL STAGE

PARAMOUNT at AHA



Last year, AHVI participated in PARAMOUNT, a Cleerly-sponsored study evaluating whether personalized care informed by artificial intelligence analysis of coronary CT angiography can improve the evaluation and management of patients with symptoms suggesting coronary artery disease.


“Can a more detailed understanding of coronary plaque help physicians make better decisions about medical treatment and further testing?”

PARAMOUNT’s primary results are scheduled for presentation on November 7, 2026, at the American Heart Association Scientific Sessions in Chicago. We look forward to learning what the findings reveal and sharing their implications with our patients and referring clinicians.

To our PARAMOUNT participants: thank you. Your involvement helped bring this research from a clinical question to a national scientific discussion.

COMING SOON

ROXI-PALISADE



AHVI is preparing to launch ROXI-PALISADE, a Phase 3 study evaluating investigational therapies targeting factor XI, a protein involved in blood clotting, in patients who have recently undergone a procedure to restore blood flow to the legs because of symptomatic peripheral artery disease.

Restoring circulation is an important step in treating PAD. Our commitment extends beyond the procedure to studying approaches that may improve patients' longer-term vascular health.

We look forward to introducing this research opportunity to eligible patients once the study opens at AHVI. Our research team will provide details about screening, participation, and study requirements.

ONGOING RESEARCH

Continuing Our Work

TRANSFORM — A Closer Look at Coronary Disease

Can prevention become more effective when treatment is guided by the amount and characteristics of coronary plaque? TRANSFORM compares AI-guided care with traditional risk-factor care to see whether this approach reduces cardiovascular events.

REACT-AF — A More Personalized Anticoagulation Strategy

Comparing continuous anticoagulation with a personalized strategy in which smartwatch-detected atrial fibrillation guides defined treatment periods in selected patients.

GREAT — Advancing PAD Treatment

The GREAT Atherectomy Trial evaluates the Golazo atherectomy device for lower-extremity revascularization in peripheral artery disease.

OCEAN(a) — Addressing Inherited Cardiovascular Risk

Focused on elevated lipoprotein(a) — an inherited cardiovascular risk factor — and an investigational treatment designed to lower it, studied through an outcomes trial and a coronary imaging substudy.

ZENITH — A New Approach to Hypertension Research

Evaluating zilebesiran, an investigational injection given every six months, in patients with uncontrolled hypertension and elevated cardiovascular risk.

V-INTERVENTION — Prevention After Intervention

Studying inclisiran to lower LDL cholesterol after coronary or peripheral vascular intervention — keeping prevention central after the procedure.



Interested in Learning More?

Patients and referring clinicians are welcome to contact our research team to discuss available studies. Eligibility and enrollment vary by trial; participation is voluntary.

Research team: 908-291-3405 · research@ahvi-nj.com

A NOTE OF THANKS

Research advances because patients volunteer, clinicians refer, and dedicated teams carry the work forward. We are grateful to everyone who makes this possible at AHVI.

Together, we are contributing to evidence that may improve how cardiovascular disease is prevented and treated — for our community and beyond.

Alexis Bellafigiore, B.S.

Clinical Operations Director, Advanced Heart and Vascular Institute of Hunterdon

Megan Angelo, B.S.

Clinical Research Coordinator, Advanced Heart and Vascular Institute of Hunterdon

Susan Sentman, RN

Clinical Research Coordinator, Advanced Heart and Vascular Institute of Hunterdon

Andrey Espinoza, MD, FACC, FSCAI, RPVI

Founder and Principal Investigator, Advanced Heart and Vascular Institute of Hunterdon

Advanced Heart and Vascular Institute of Hunterdon conducts clinical research in cardiovascular prevention and treatment. For study information, contact the research team at 908-291-3405 or research@ahvi-nj.com. 200 State Route 31, Suite 101, Flemington, NJ 08822.